CLB Stock Analysis: Core Laboratories | NYSE
Oil & Gas Equipment & Services | NYSE, USA | Market Cap: 571m USD | 12M Return: 21.6% | US21867A1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.56M
EPS Trend: -71.8%
Qual. Beats: 1
Rev. Trend: 74.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Core Laboratories (NYSE: CLB) is a Houston-based provider of reservoir description and production enhancement services to the oil and gas industry, operating domestically and internationally since its founding in 1936. The company is organized into two segments: Reservoir Description, which offers laboratory-based analytical and field services to characterize reservoir rock and fluids, and Production Enhancement, which provides services and products for well completions, perforations, stimulations, production, and well abandonment. Within the broader Energy sector (GICS sub-industry: Oil & Gas Equipment & Services), CLB supplies specialized technical inputs to upstream exploration and production operators rather than producing hydrocarbons itself.
In addition to its core oil and gas offerings, Core Laboratories extends its reservoir analysis capabilities into adjacent areas such as carbon capture, utilization and storage (CCUS), geothermal energy projects, and mining evaluation, reflecting how oilfield services firms increasingly apply subsurface expertise to energy transition applications. The company markets its products and services through a multi-channel approach combining direct sales representatives, technical seminars, trade shows, print advertising, and third-party distributors.
- Global E&P capital spending drives Reservoir Description segment revenue
- Crude oil prices and U.S. completions activity boost Production Enhancement demand
- Energy transition services in CCUS and geothermal expand revenue mix
- Share repurchases and dividends support capital return to shareholders
| Net Income: 24.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -4.70 > 1.0 |
| NWC/Revenue: 21.82% < 20% (prev 25.69%; Δ -3.86% < -1%) |
| CFO/TA 0.05 > 3% & CFO 28.2m > Net Income 24.4m |
| Net Debt (193.6m) to EBITDA (62.6m): 3.09 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.9m) vs 12m ago -1.33% < -2% |
| Gross Margin: 18.12% > 18% (prev 16.71%; Δ 1.40% > 0.5%) |
| Asset Turnover: 87.34% > 50% (prev 85.93%; Δ 1.41% > 0%) |
| Interest Coverage Ratio: 4.35 > 6 (EBIT TTM 47.8m / Interest Expense TTM 11.0m) |
| A: 0.19 (Total Current Assets 214.4m - Total Current Liabilities 101.0m) / Total Assets 586.8m |
| B: 0.30 (Retained Earnings 176.9m / Total Assets 586.8m) |
| C: 0.08 (EBIT TTM 47.8m / Avg Total Assets 594.4m) |
| D: 0.89 (Book Value of Equity 272.7m / Total Liabilities 308.0m) |
| Altman-Z'' = 3.72 = AA |
| DSRI: 0.90 (Receivables 116.1m/128.0m, Revenue 519.2m/517.4m) |
| GMI: 0.92 (GM 16.71% / 18.12%) |
| AQI: 1.06 (AQ_t 0.37 / AQ_t-1 0.35) |
| SGI: 1.00 (Revenue 519.2m / 517.4m) |
| TATA: -0.01 (NI 24.4m - CFO 28.2m) / TA 586.8m) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of August 20, 2026, the stock is trading at USD 12.65 with a total of 329,934 shares traded. Over the past week, the price has changed by +1.61%, over one month by +13.15%, over three months by -7.72% and over the past year by +21.63%.
Current recommended Stop Loss: 11.90 (which is 5.9% or 1.4 ATR below the current price).
Core Laboratories has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CLB.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 15.2 | 19.9% |
P/E Trailing = 23.9423
P/E Forward = 19.7628
P/S = 1.1003
P/B = 2.0951
P/EG = 1.6717
Revenue TTM = 519.2m USD
EBIT TTM = 47.8m USD
EBITDA TTM = 62.6m USD
Long Term Debt = 113.9m USD (from longTermDebt, last quarter)
Short Term Debt = 11.9m USD (from shortTermDebt, last quarter)
Debt = 216.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.3m
Net Debt = 193.6m USD (calculated: Debt 216.4m - CCE 22.7m)
Enterprise Value = 764.9m USD (571.3m + Debt 216.4m - CCE 22.7m)
Interest Coverage Ratio = 4.35 (Ebit TTM 47.8m / Interest Expense TTM 11.0m)
EV/FCF = 71.28x (Enterprise Value 764.9m / FCF TTM 10.7m)
FCF Yield = 1.40% (FCF TTM 10.7m / Enterprise Value 764.9m)
FCF Margin = 2.07% (FCF TTM 10.7m / Revenue TTM 519.2m)
Net Margin = 4.69% (Net Income TTM 24.4m / Revenue TTM 519.2m)
Gross Margin = 18.12% ((Revenue TTM 519.2m - Cost of Revenue TTM 425.1m) / Revenue TTM)
Gross Margin QoQ = 18.65% (prev 16.19%)
Tobins Q-Ratio = 1.30 (Enterprise Value 764.9m / Total Assets 586.8m)
Interest Expense / Debt = 5.08% (Interest Expense 11.0m / Debt 216.4m)
Taxrate = 32.89% (12.1m / 36.8m)
NOPAT = 32.1m (EBIT 47.8m * (1 - 32.89%))
Current Ratio = 2.12 (Total Current Assets 214.4m / Total Current Liabilities 101.0m)
Debt / Equity = 0.79 (Debt 216.4m / totalStockholderEquity, last quarter 272.7m)
Debt / EBITDA = 3.09 (Net Debt 193.6m / EBITDA 62.6m)
Debt / FCF = 18.04 (Net Debt 193.6m / FCF TTM 10.7m)
Total Stockholder Equity = 269.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.10% (Net Income 24.4m / Total Assets 586.8m)
RoE = 9.03% (Net Income TTM 24.4m / Total Stockholder Equity 269.7m)
RoCE = 12.46% (EBIT 47.8m / Capital Employed (Equity 269.7m + L.T.Debt 113.9m))
RoIC = 6.75% (NOPAT 32.1m / Invested Capital 474.9m)
WACC = 8.10% (E(571.3m)/V(787.6m) * Re(9.88%) + D(216.4m)/V(787.6m) * Rd(5.08%) * (1-Tc(0.33)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -80.62 | Cagr: -0.77%
[DCF] Terminal Value 73.10% ; FCFF base≈22.2m ; Y1≈19.4m ; Y5≈15.7m
[DCF] Fair Price = 1.27 (EV 251.9m - Net Debt 193.6m = Equity 58.3m / Shares 45.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -71.75 | EPS CAGR: -8.06% | SUE: 1.20 | # QB: 1
Revenue Correlation: 74.24 | Revenue CAGR: 0.95% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.15 | Chg30d=-7.09% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=0.45 | Chg30d=-1.10% | Revisions=-25% | GrowthEPS=-40.0% | GrowthRev=-3.1%
EPS next Year (2027-12-31): EPS=0.70 | Chg30d=+0.24% | Revisions=-40% | GrowthEPS=+54.8% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -57% (up=0, down=4)